# Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity

> **NCT03759782** · PHASE3 · UNKNOWN · sponsor: **Ottawa Hospital Research Institute** · enrollment: 24 (estimated)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** Tenofovir

## Key facts

- **NCT ID:** NCT03759782
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-10
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-09-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03759782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03759782, "Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03759782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*